Cargando…

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case

Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutlu, Yasa Gul, Yıgıt Kaya, Sureyya, Maral, Senem, Melek, Elif, Baslar, Zafer, Kaynar, Leylagul, Sevindik, Omur Gokmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611496/ https://www.ncbi.nlm.nih.gov/pubmed/37901215 http://dx.doi.org/10.3389/fimmu.2023.1276295

Ejemplares similares

Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
por: Yiğit Kaya, Süreyya, et al.
Publicado: (2023)

Persistent Polyclonal B-Cell Lymphocytosis with Binucleated Lymphocytes
por: Balık Aydın, Berrin, et al.
Publicado: (2021)

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
por: Karakus, Volkan, et al.
Publicado: (2022)

Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas?
por: Gül Mutlu, Yaşa, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Successful Treatment of Gastric Relapse in Multiple Myeloma with Bortezomib after Autologous Hematopoietic Stem Cell Transplantation (autoHSCT)
por: Sivgin, Serdar, et al.
Publicado: (2013)

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Dalovisio, A., et al.
Publicado: (2022)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
por: Mol, Isha, et al.
Publicado: (2023)

Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
por: Solmaz, Serife, et al.
Publicado: (2018)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
por: Mohty, Mohamad, et al.
Publicado: (2023)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

Candida esophagitis incidentally detected by 18F‐FDG PET/CT in a patient with CNS lymphoma
por: Bayar, Melikşah, et al.
Publicado: (2021)

PB2131: MAGNETISMM-7: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF ELRANATAMAB VERSUS LENALIDOMIDE IN POST-TRANSPLANT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Manteca, Maria Victoria Mateos, et al.
Publicado: (2023)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Grosicki, Sebastian, et al.
Publicado: (2023)

Flow Cytometry Method as a Diagnostic Tool for Pleural Fluid Involvement in a Patient with Multiple Myeloma
por: Keklik, Muzaffer, et al.
Publicado: (2012)

CNS Genes Implicated in Relapse
por: Kuntz-Melcavage, Kara L, et al.
Publicado: (2008)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
por: Beksac, Meral, et al.
Publicado: (2023)

Secondary CNS myeloma with remission after systemic CNS-penetrating agents
por: Fernandez, Luis G, et al.
Publicado: (2022)

Intradiploic Hematoma in a Hemophilic Patient: Hemophilic Pseudotumor of Calvarium
por: Hanımoğlu, Hakan, et al.
Publicado: (2017)

A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
por: GEMİCİ, Aliihsan, et al.
Publicado: (2020)

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
por: Çetin, Güven, et al.
Publicado: (2014)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Relapse pattern and prognosis of primary CNS lymphoma
por: Dahiya, Saurabh, et al.
Publicado: (2012)

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
por: Güven, Zeynep Tuğba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7hdnld402aso2aq68plkng27vs